Bahattin Tanrıkulu

Dr. Bahattin Tanrıkulu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
CHChafik Handis
Chafik Handis
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
ADAyça Erşen Danyeli
Ayça Erşen Danyeli
MÖM. Memet Özek
M. Memet Özek


29 May 2019 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
MÖM. Memet Özek
M. Memet Özek

4 July 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
AYAhmet Harun Yaşar
Ahmet Harun Yaşar
CCCengiz Canpolat
Cengiz Canpolat
FÇFunda Çorapçıoğlu
Funda Çorapçıoğlu
ETEvrim Tezcanli
Evrim Tezcanli
MÖM. Memet Özek
M. Memet Özek

26 December 2017 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
FMFahmida Arab Mallah
Fahmida Arab Mallah
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
FÇFunda Çorapçıoğlu
Funda Çorapçıoğlu
MÖM. Memet Özek
M. Memet Özek

1 January 2020 in Turkish Neurosurgery
Verified
Journal Article
Closed access
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
MOM. Memet Ozek
M. Memet Ozek
AIM: To share our clinical experience with surgical and adjuvant treatment strategies followed during the treatment of midline gliomas. MATERIAL and METHODS: Pediatric patients with midline gliomas who underwent surgery in our clinic between March 2016 and November 2019 were included. Tissue samples were obtained through surgical excision, open biopsy, or stereotactic biopsy. All samples were analyzed for ATRX, BRAFV600E, IDH1/2, H3K27M, and H3G34R mutations, EGFR and PGFRA amplifications, and PTEN loss. RESULTS: There were 7 (43.8%) female and 9 (56.2%) male pediatric patients in the study. Eight patients had thalamic, 5 patients had pontine, 2 patients had medulla oblongata and one patient had brachium pontis tumors. Presenting symptoms were headache, disequilibrium, ophthalmoplegia, and panic attack. Eleven tumors showed H3K27M mutation and were diagnosed as diffuse midline gliomas. BRAFV600E, ATRX mutations, PTEN loss, and EGFR amplifications were other molecular alterations detected within tumor samples. Patients with H3K27M mutant tumors had a shorter life span. Five patients were enrolled in an ONC201 trial. CONCLUSION: Although most midline gliomas are not amenable to gross total excision, obtaining tissue samples is mandatory for determining patients' exact diagnoses, tailored treatment plans, and eligibility for clinical trials. Stereotactic biopsy for midline gliomas is a safe and effective method.